Membranes play a critical role in the downstream purification of biotherapeutics like monoclonal antibodies. Current sales of biotherapeutics are more than $150 billion/yr; these products are a critical component of today’s healthcare system (with total healthcare expenditures exceeding $3 trillion / yr). Membranes are used for initial clarification, bioburden reduction, virus removal, product concentration and formulation, and sterile filtration. The production of these life-saving products would be impossible without membrane technology. The global annual market for membrane filtration in the bio-pharmaceutical industry was approximately $3.5 billion in 2016 .
A number of recent developments have spurred further interest in membranes for bioprocessing. This includes significant economic pressures associated with the growth in low-cost international manufacturers and the advent of biosimilars (generic versions of biotherapeutics). There is also significant interest in transitioning from batch to continuous operations. Robert Bradway, the CEO of Amgen, has noted that “Today’s systems for producing drugs in bacterial or animal cells and then isolating them are hugely expensive and can take months. With more efficient processes in place, companies could swiftly increase production of drugs in high demand, and they could produce medicines for rare diseases more cost-effectively as well”. New membrane separations technologies will be needed to meet the demands for continuous bioprocessing.
Performance and scale up issues for depth filtration bioprocesses 
Ultrafiltration / Diafiltration of Antibody Products 
Purification of Nucleic Acids for Gene Therapy Applications
Purification of Conjugate Vaccines using Membrane Filtration 
Virus Removal Filtration using the Viresolve Pro 
